{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/adverse-drug-reactions/background-information/health-financial-implications-of-adrs/","result":{"pageContext":{"chapter":{"id":"2bf3267e-f0ed-5301-b659-3a0d290262bc","slug":"health-financial-implications-of-adrs","fullItemName":"Health and financial implications of ADRs","depth":2,"htmlHeader":"<!-- begin field 5acec371-1520-4c37-9f07-eead8e566d60 --><h2>What are the health and financial implications of adverse drug reactions?</h2><!-- end field 5acec371-1520-4c37-9f07-eead8e566d60 -->","summary":"","htmlStringContent":"<!-- begin item 408c3a4b-9300-48ea-94eb-6b73e2d3a9ee --><!-- begin field fc447bde-5c66-48a1-a71f-f6b2194151c5 --><ul><li><strong>The health and financial implications of adverse drug reactions (ADRs) are significant.</strong><ul><li>The precise numbers of ADRs that occur cannot be determined, given the difficulties in assessing causality and the low proportion of ADRs that are reported [<a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">BMA Board of Science, 2006</a>].</li><li>Most research has tried to quantify ADRs by evaluating hospitalized patients, and admissions in particular [<a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">BMA Board of Science, 2006</a>]:<ul><li>The percentage of hospital admissions due to ADRs in the UK has been estimated to be 6–7% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">Smith et al, 1996</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">Bandolier, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">Pirmohamed et al, 2004</a>]. One systematic review found 3.73% (range 1.36–15.42) of hospital admissions to be preventable and drug-related [<a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">Howard et al, 2007</a>].</li><li>ADRs are thought to occur in 10–20% of hospital in-patients. In one study, over 2% of people admitted with an ADR (approximately 0.15% of all people admitted) died [<a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">Pirmohamed et al, 2004</a>].</li><li>A systematic review estimated that the overall impact of ADRs in England was four out of 100 hospital bed-days, or about fifteen to twenty 400-bed hospital equivalents at a cost of about £380 million a year to the NHS in England [<a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">Bandolier, 2002</a>].</li><li>A meta-analysis assessed the percentage of patients with preventable ADRs as well as the preventability of ADRs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">Hakkarainen, 2012</a>]. For outpatients (n = 48,797 emergency visits/hospital admissions), the evidence showed that 2% had preventable ADRs, and 52% of ADRs present at the time of hospitalization/emergency visit were assessed as preventable. For inpatients (n = 24,128 inpatients), the results showed that 1.6% had preventable ADRs during hospital stay, and 45% of ADRs were assessed as preventable. </li></ul></li></ul></li><li><strong>According to the The Medicines and Healthcare Products Regulatory Agency (MHRA), ADRs</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">MHRA, 2015a</a>]<strong>:</strong><ul><li>Adversely affect patients’ quality of life and can also cause patients to lose confidence in the healthcare system.</li><li>Contribute to increased costs of patient care and can lengthen hospital stays.</li><li>May mimic disease, resulting in unnecessary investigations and delays in treatment.</li></ul></li></ul><!-- end field fc447bde-5c66-48a1-a71f-f6b2194151c5 --><!-- end item 408c3a4b-9300-48ea-94eb-6b73e2d3a9ee -->","topic":{"id":"5891f47f-d14e-5ade-b43e-09ab2ee894c3","topicId":"fb7af4be-ae9d-4213-b2ca-ca17ddb868c1","topicName":"Adverse drug reactions","slug":"adverse-drug-reactions","lastRevised":"Last revised in March 2017","chapters":[{"id":"78737b02-a5d5-5686-924f-3bd67a984373","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"3124c32f-664e-57ef-805a-95067102ad32","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"23e3d730-4bbb-5a3a-bd97-77a17bee3f53","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0974ec45-5b01-515b-b02e-5cad23aacea1","slug":"changes","fullItemName":"Changes"},{"id":"6474141f-1642-5857-9d25-033f3b7503f0","slug":"update","fullItemName":"Update"}]},{"id":"5bad1097-961b-5653-8f9b-6456f05b7836","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"6be883ff-72cf-54e9-b064-31f4df584e67","slug":"goals","fullItemName":"Goals"},{"id":"c6cc81cc-134f-5d98-b79c-967bf65bddd3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"95dab13c-419c-5de3-b7fd-95118f8b48e5","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d675aba3-9d84-5b1a-9c2b-79cc7bcab6c3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cd63cb73-82b3-5c83-bea6-b82fa98f7888","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"977ca222-407c-5643-a723-eeee2b2f6c0f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b68bacaa-d4b5-58a7-b9d6-46bf7c82f8ad","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"26252f90-7908-554e-8535-a49168c8bf4a","slug":"definition","fullItemName":"Definition"},{"id":"68cfd9ca-f6d9-582b-a898-39bd0927455f","slug":"categorization-of-adrs","fullItemName":"Categorization of ADRs"},{"id":"2bf3267e-f0ed-5301-b659-3a0d290262bc","slug":"health-financial-implications-of-adrs","fullItemName":"Health and financial implications of ADRs"},{"id":"804b9155-4dc6-574d-b5b3-3e320dd07967","slug":"monitoring-adverse-drug-reactions","fullItemName":"Monitoring adverse drug reactions"}]},{"id":"753ee7eb-1c21-5cf5-8e2e-e0e3ebd8be4a","fullItemName":"Management","slug":"management","subChapters":[{"id":"1d7dbb3f-b730-5e84-aea1-49ed9234a126","slug":"adverse-drug-reactions","fullItemName":"Scenario: Adverse drug reactions"}]},{"id":"95500d82-4a44-5f81-befc-15cfb88abd53","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"77a8b838-04cb-5545-affe-c92faa19e1bb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"dfa6f9b0-4f82-5b25-99fb-5ce802d731e8","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f85a17d1-c7b8-5ebf-a80c-88c2f6c69eff","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5aee896a-ac4b-5a54-bde2-0577412d6418","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"8054ea0e-276d-5167-818e-fec1d38114aa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1a62db49-0d92-514d-9a4a-dfa05227ec25","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"86d8d508-d776-5c0a-be24-6df70fb79006","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b68bacaa-d4b5-58a7-b9d6-46bf7c82f8ad","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}